Topadur Pharma

Zurich-Schlieren, Switzerland, 7 September 2023

We are thrilled to announce that TOPADUR Pharma AG has once again been recognized as one of Switzerland's top 25 scale-up companies.

This achievement is a demonstration to our team's dedication and our partners' support.

We are grateful for this recognition and remain committed to pushing the boundaries of innovation in the years to come.

Please check out the link below.

‍

3.7.20

Press Release

Dr. Daniel L. Vasella new member of the Board of Directors

The shareholders of the company elected today Dr. Daniel L. Vasella, as new member to the Board of Directors.

15.10.21

Press Release

EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.

7.4.22

Press Release

Pulmonary fibrosis is a chronic and usually fatal disease. The project will investigate the anti-fibrotic effects of TOP-V122.